PMID: 15356128Sep 10, 2004Paper

Enhanced responses of glycosylphosphatidylinositol anchor-deficient T lymphocytes

The Journal of Immunology : Official Journal of the American Association of Immunologists
Wouter L W HazenbosTaroh Kinoshita

Abstract

The functions of GPI-anchored proteins in T lymphocyte activation have been controversial. This issue was addressed by studying the responses of T lymphocytes from T lymphocyte-specific GPI anchor-deficient mice to different stimuli that normally allow coligation of TCR and GPI-anchored proteins. Stimulation of GPI anchor-deficient T lymphocytes with ConA induced 2-fold higher proliferative responses than did normal cells. In response to allogeneic stimulation, proliferation of GPI anchor-deficient T lymphocytes was enhanced 2- to 3-fold. The response to ConA of a GPI anchor-deficient anti-OVA T lymphocyte clone generated from these mice was approximately 3-fold higher than that of cells from the same clone in which GPI anchor expression was restored by retroviral transduction. The response of the GPI anchor-deficient cloned anti-OVA T lymphocytes to antigenic stimulation was similar to that of the retrovirally restored cells. These results indicate that coligation with GPI-anchored proteins counteracts the response to TCR stimulation by ConA or alloantigen but not protein Ag.

References

Sep 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·S VolarevićJ D Ashwell
Apr 1, 1986·The Journal of Experimental Medicine·J SprentR Korngold
Jun 1, 1993·Current Opinion in Immunology·D Brown
Aug 1, 1996·The Journal of Clinical Investigation·K RajewskyF Schwenk
Sep 17, 1996·Proceedings of the National Academy of Sciences of the United States of America·R G HawleyS J Goldman
Jun 5, 1997·Nature·K Simons, E Ikonen
Jul 8, 1997·Proceedings of the National Academy of Sciences of the United States of America·M TarutaniJ Takeda
Feb 3, 1999·Proceedings of the National Academy of Sciences of the United States of America·J González-CabreroH Reiser
Aug 4, 1999·Immunology Today·V HorejsíH Stockinger
Dec 7, 2002·Molecular and Biochemical Parasitology·Thomas Naderer, Malcolm J McConville
Mar 5, 2003·Annual Review of Immunology·Michelle DykstraSusan K Pierce
Mar 12, 2003·International Journal of Hematology·Norimitsu InoueTaroh Kinoshita

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.